In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
Two years ago the board of directors of Alexion Pharmaceuticals Inc. began a seismic overhaul of its leadership, strategy and pipeline. The Boston-based rare disease specialist had success with Soliris (eculizumab), its blockbuster first-in-class complement inhibitor, but needed to prove to shareholders where the next revenue streams were coming from.
A less-than successful $8.4bn takeover of Synageva BioPharma Corp. in 2015, which brought in the slow-selling Kanuma (sebelipase alfa),...
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.
